Omeros Corporation Analysis

Company Overview

Omeros Corporation (NASDAQ: OMER) is a clinical-stage biopharmaceutical company based in Seattle, Washington. The company specializes in discovering, developing, and commercializing small-molecule and protein therapeutics targeting immunologic diseases. Omeros has a workforce of approximately 239 employees.

Recent Developments

On May 12, 2025, Omeros announced agreements regarding $80.5 million of its 5.25% Convertible Senior Notes due 2026. The company entered into exchange agreements with select investors to convert $70.5 million of these notes into newly issued 9.50% Convertible Senior Notes due 2029. This transaction is expected to close on May 14, 2025, and aims to extend the maturity of a significant portion of the company's outstanding debt. Additionally, Omeros has entered into a Note Conversion Agreement to convert $10 million of the 2026 Convertible Notes into shares of common stock.

In another update, Omeros reported progress in its Phase 3 clinical trials for zaltenibart (OMS906), targeting paroxysmal nocturnal hemoglobinuria (PNH), and announced successful results from the pivotal trial for narsoplimab, which is designed to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Financial Analysis

As of May 12, 2025, Omeros' stock price is $4.3950, reflecting a change of -28.88%. The company has a market capitalization of approximately $360.33 million and an enterprise value of $477.22 million. The average trading volume is reported at 2,352,904 shares.

Key Financial Metrics

Metric	Value
Stock Price	$4.3950
Market Capitalization	$360.33 million
Enterprise Value	$477.22 million
Average Trading Volume	2,352,904 shares
52 Week Price Range	$3.00 - $13.60
Earnings Per Share (EPS)	-3.14
Net Income (TTM)	-$182.63 million

Omeros reported a net loss of $182.63 million over the trailing twelve months (TTM), with an EPS of -3.14. The company anticipates a reduction in its outstanding debt obligations from $117.9 million to approximately $17.4 million over the next 12 months due to recent financial maneuvers.

Market Position and Industry Context

Omeros operates within the biotechnology sector, focusing on therapies for rare diseases. The company aims to address significant medical needs through its pipeline of therapeutics, including zaltenibart and narsoplimab. The competitive landscape includes other biopharmaceutical companies targeting similar indications.

The company's recent clinical trial advancements and financial restructuring may enhance its market position, potentially attracting further investment and partnerships.

TL;DR

Omeros Corporation is a clinical-stage biopharmaceutical company with a current stock price of $4.3950, down 28.88%. On May 12, 2025, the company announced agreements to restructure $80.5 million of its convertible senior notes, which could significantly alter its debt obligations. Omeros is advancing its clinical trials for zaltenibart and narsoplimab, which target rare diseases. The company has a market capitalization of approximately $360.33 million and reported a net loss of $182.63 million over the past year.